MedWatch

Eli Lilly acquires biotech firm in new insulin venture

A new form of insulin drugs at Protomer Technoloigies caught the eye of Eli Lilly, which has bought the firm for a sum that could surpass USD 1bn (DKK 6.3bn).

Photo: Mike Blake/REUTERS / X00030

US pharmaceutical company Eli Lilly has entered into an agreement to acquire biotech company Protomer Technologies for a price that could total more than USD 1bn. The final figure will be dependent on future performance and milestone payments.

Protomer Technologies owns a peptide and protein platform which can identify and measure substances including glucose.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs